Bacterial antimicrobial resistance (AMR) was associated with 4.95 million deaths in 2019, of which 1.27 million were directly attributable to resistance.
Original statement
4.95 مليون وفاة مرتبطة بمقاومة المضادات في عام واحد، منها 1.27 مليون منسوبة مباشرة إلى المقاومة البكتيرية
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Bacterial antimicrobial resistance (AMR) was associated with 4.95 million deaths in 2019, of which 1.27 million were directly attributable to resistance.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (eltayebat.com)
- Origin
- https://eltayebat.com/rule/antibiotic-overuse/
- Attribution uncertainty
- Archive editorial narrative and featured-study cards, written by the archive operators; study selection is the archive's, not necessarily Elawady's.
- Claimed mechanism
Resistant infections.
- Claimed health effect
Deaths.
- Population concerned
Global
- Geographic restriction by Elawady
none found
Scientific assessment
True – The statement is supported by robust evidence.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
AMR burden figures.
2. What is demonstrably correct?
4.95 million (95% UI 3.62-6.57) associated and 1.27 million (0.911-1.71) attributable deaths in 2019 (A-ABX-18). The GBD 2021 analysis re-estimated 2019 at 4.94 million (4.43-5.45) associated and 1.20 million (1.05-1.35) attributable deaths, and gives 4.71 million associated and 1.14 million attributable for 2021; forecast 1.91 million attributable and 8.22 million associated deaths in 2050 (I-ABX-01). WHO Eastern Mediterranean Region (includes Egypt): 380,000 associated and 92,800 attributable deaths in 2021 (I-ABX-02).
3. What is wrong or exaggerated?
Nothing wrong with the numbers; they are model estimates, not counts.
4. What remains unclear?
Uncertainty in data-poor countries.
5. Which studies support it?
6. Which studies contradict it?
None. The later GBD 2021 analysis gives slightly different figures for the same year 2019 (1.20 instead of 1.27 million attributable; 4.94 instead of 4.95 million associated) and lower figures for 2021 (I-ABX-01); the claim's figures correspond to the earlier publication and remain broadly consistent. All figures are model estimates with uncertainty intervals.
7. What applies to Germany and Europe?
Australasia lowest attributable rate (6.5/100,000), western sub-Saharan Africa highest (27.3/100,000) in 2019 (A-ABX-18).
8. What is known about Egypt?
In 2019 the attributable rate for North Africa and Middle East was 11.2 per 100,000 (Table 2 of A-ABX-18, read via PMC web page).
9. What practical conclusion is appropriate?
AMR is a major threat; the GBD authors also stress that better access to appropriate antibiotics could avert many deaths (I-ABX-01).
Assessment details
- Rationale for certainty of evidence
Correctly reported from GBD modelling; estimates have wide uncertainty intervals and are model-based, especially for data-poor regions. The later GBD 2021 analysis re-estimated 2019 at 4.94 million associated and 1.20 million attributable deaths, and gives 4.71 million and 1.14 million for 2021 (I-ABX-01).
- Source quality
Large systematic modelling study (Lancet).
- Regional transferability
Global; highest burden in low-resource settings.
- Individual exceptions
Not applicable.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically well supported – The claim agrees with consistent, high-quality evidence.
Research question: How many deaths in 2019 were associated with and attributable to bacterial antimicrobial resistance according to the best available estimates?
Research question in detail (PECO)
- Population
- Global population, 2019
- Intervention or exposure
- Infections with resistant bacteria
- Comparison
- Counterfactuals: no infection (associated) and susceptible infection (attributable)
- Geographic scope
- Global; highest burden in low-resource regions
- Outcomes
- Associated deaths
- Attributable deaths
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Global deaths from antibiotic resistance (2019)
Antimicrobial Resistance Collaborators. Lancet 2022 · PMID 35065702 · DOI 10.1016/S0140-6736(21)02724-0 Risk assessmentfull text checkedGBD 2019 AMR analysis (Lancet 2022).
- Actual result
- 4.95 million (3.62-6.57) associated and 1.27 million (0.911-1.71) attributable deaths in 2019.
- Methodological quality
- high for a modelling study (large data, transparent methods)
- Relevance
- direct: the source of the claim
- Limitations
- Model estimates; sparse data in LMICs.
Antibiotic resistance deaths 1990-2050
GBD 2021 Antimicrobial Resistance Collaborators. Lancet 2024 · PMID 39299261 · DOI 10.1016/S0140-6736(24)01867-1 Risk assessmentfull text, structured risk-of-bias assessmentGBD 2021 AMR re-estimate (Lancet 2024).
- Actual result
- 2019 re-estimated: 4.94 million (4.43-5.45) associated, 1.20 million (1.05-1.35) attributable.
- Methodological quality
- high for a modelling study
- Relevance
- direct: independent re-estimation of the same year
- Limitations
- Model estimates.
What speaks against the claim?
No high-quality evidence against the claim was found.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
The figures are correctly reported from the 2022 GBD analysis; a 2024 re-estimate gives very similar values for 2019.
Why some studies weigh more
Both GBD rounds use the same framework; they are not independent confirmations but the later round uses more data.
Is a causal relationship established? Not applicable Burden estimate, not a causal claim about a single exposure.
Remaining uncertainty
Wide uncertainty in data-poor regions; attributable deaths depend on the counterfactual chosen.
Justified conclusion
Correctly reproduced.
Why do studies seem to disagree?
No conflict; small differences between GBD rounds reflect updated data and methods.
Does this depend on the country?
- General biological effects
- Universal problem.
- Eating habits
- Not applicable (medicine use, not diet).
- Legal rules
- Not applicable.
- Actual monitoring data
- WHO Eastern Mediterranean Region (including Egypt): 92,800 attributable deaths in 2021 (I-ABX-02).
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- CI plausibility – Not recalculated: GBD uncertainty intervals are model-based (not normal-theory CIs); no counts for recalculation. not recalculable from the published data
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Global AMR deaths 2019
- Starting level
- low (observational studies)
- Reasons for downgrading
- indirectness/imprecision of modelled data in low-data regions (minor)
- Reasons for upgrading
- Large, consistent, re-estimated
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | TITLE:("antimicrobial resistance") AND TITLE:(burden) AND TITLE:(global OR "systematic analysis") AND PUB_YEAR:[2024 TO 2026] | both directions | 37 | |
| Europe PMC | 26 October 2026 | (antimicrobial resistance) AND (deaths OR burden) AND (Egypt OR Egyptian) AND ("systematic analysis" OR GBD OR "global burden") | both directions | 1035 |
Open questions
Future GBD rounds.
How deeply was this checked?
3 linked studies: 2 checked in full text (1 of them with a structured risk-of-bias assessment), 1 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: True (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: True (moderate)
No new global estimate beyond GBD 2021 (already linked) was found; the claim remains correctly reported.
In plain language
Researchers estimated that in 2019 about 1.27 million deaths worldwide were directly caused by antibiotic-resistant bacteria. A newer analysis estimated 1.14 million for 2021. These are model estimates with some uncertainty. The same researchers say that better access to the right antibiotics is part of the solution.
Studies on this claim
Studies supporting the claim (3)
-
Global deaths from antibiotic resistance (2019)
Antimicrobial Resistance Collaborators. Lancet 2022 · PMID 35065702 · DOI 10.1016/S0140-6736(21)02724-0Risk assessmentcited by the Tayebat archivefull text checked★ key studyAbout 1.27 million deaths were directly caused by resistant bacteria in 2019.
Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate AMR burden.
- How was the study done?
Global modelling.
- How many people, animals or samples were studied?
471 million records.
- What was actually found?
1.27 M attributable, 4.95 M associated deaths.
- How large was the observed effect?
Regional rates 6.5-27.3/100,000.
- What do the results mean in everyday life?
Resistance is a leading killer.
- What are the study's limitations?
Model estimates.
- What does it say about Elawady's specific claim?
Supports burden claim; not 'combined'.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Exact counts.
-
Antibiotic resistance deaths 1990-2050
GBD 2021 Antimicrobial Resistance Collaborators. Lancet 2024 · PMID 39299261 · DOI 10.1016/S0140-6736(24)01867-1Risk assessmentindependent cross-checkfull text, structured risk-of-bias assessment★ key studyAbout 1.14 million deaths were caused by resistance in 2021; better care and access to antibiotics could prevent tens of millions of deaths.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track AMR burden.
- How was the study done?
GBD modelling.
- How many people, animals or samples were studied?
520 million records.
- What was actually found?
2021: 1.14 million deaths caused by resistance and 4.71 million deaths with a resistant infection; deaths in children under 5 fell by more than half since 1990, but rose by over 80% in people 70 and older.
- How large was the observed effect?
1.91 M forecast for 2050.
- What do the results mean in everyday life?
Resistance is rising; access to the right antibiotics matters.
- What are the study's limitations?
Model estimates; little data in many poorer countries; forecasts depend on assumptions.
- What does it say about Elawady's specific claim?
Supports burden; contradicts refusing antibiotics.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Exact counts.
-
Antibiotic resistance in the Eastern Mediterranean
EMR Antimicrobial Resistance Collaborators. Lancet Public Health 2025 · PMID 41082884 · DOI 10.1016/S2468-2667(25)00201-4Risk assessmentindependent cross-checkabstract checkedAbout 92,800 deaths in the region were attributed to resistance in 2021.
Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Regional AMR burden.
- How was the study done?
Modelling.
- How many people, animals or samples were studied?
EMR.
- What was actually found?
92,800 attributable deaths.
- What do the results mean in everyday life?
Relevant to Egypt.
- What are the study's limitations?
Model.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Low.
- What can explicitly not be concluded from this study?
Egypt-level numbers.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Australasia lowest attributable rate (6.5/100,000), western sub-Saharan Africa highest (27.3/100,000) in 2019 (A-ABX-18).
Egypt
In 2019 the attributable rate for North Africa and Middle East was 11.2 per 100,000 (Table 2 of A-ABX-18, read via PMC web page).
What applies in my country?
General scientific assessment
True Correctly reported.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.. Antimicrobial Resistance Collaborators. Lancet 2022 · PMID 35065702 · DOI 10.1016/S0140-6736(21)02724-0
- Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.. GBD 2021 Antimicrobial Resistance Collaborators. Lancet 2024 · PMID 39299261 · DOI 10.1016/S0140-6736(24)01867-1
- The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990-2021: a cross-country systematic analysis with forecasts to 2050.. EMR Antimicrobial Resistance Collaborators. Lancet Public Health 2025 · PMID 41082884 · DOI 10.1016/S2468-2667(25)00201-4